skip to Main Content

Chemotherapy Triplet Elicits Encouraging Activity in Pancreatic Adenocarcinoma

Newsfeed image, light gray text on dark gray background
The addition of cisplatin to gemcitabine and nab-paclitaxel (Abraxane) resulted in encouraging activity in patients with previously untreated advanced pancreatic cancer, despite not having demonstrated the prespecified number of complete responses (CRs) to meet the primary endpoint of a phase Ib/II clinical trial (NCT01893801), according to findings published in JAMA Oncology.

Read more . . . 


Back To Top